- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
29
Premature Ejaculation
Chris G. McMahon
Introduction
Over the past 20–30 years,the PE treatment para digm, previously limited to behavioral psy chotherapy, has expanded to include drug treatment.1,2 Animal and human sexual psychop harmacological studies have demonstrated that serotonin and 5HT receptors are involved in ejaculation and confirm a role for SSRIs in the treatment of PE.36 Multiple wellcontrolled evi dencebased studies have demonstrated the effi cacy and safety of SSRIs in delaying ejaculation, confirming their role as firstline agents for the treatment of lifelong and acquired PE.7 More recently,there has been increased attention to the psychosocial consequences of PE, its epidemiol ogy, its etiology, and its pathophysiology by both clinicians and the pharmaceutical industry.813
poorly validated definitions of PE.11,13,19 A multi national, communitybased, ageranging stop watch IELT study demonstrated that the distribution of the IELT was positively skewed, with a median IELT of 5.4 min (range, 0.55–44.1 min), decreased with age, and varied between countries.10 (Fig. 29.1) Using an epidemiological approach to assess PE risk, the authors regarded the 0.5 and 2.5 percentiles as acceptable stan dards of disease definition in this type of skewed distribution, and proposed that men with an IELT of less than 1 min (belonging to the 0.5 percentile) have “definite” PE, while men with IELTs between 1 and 1.5 min (between 0.5 and 2.5 percentile) have “probable” PE.20 These nor mative data support the notion that IELTs of less than 1 min are statistically abnormal compared to men in the general Western population.
Epidemiology
Premature ejaculation (PE) has been estimated to occur in 4–39% of men in the general com munity.12,1419 and is often reported as the most common male sexual disorder, despite a sub stantial disparity between the selfreported inci dence of PE in epidemiological studies19 and that suggested by communitybased normative stopwatch intravaginal ejaculation latency time (IELT) studies.10 However, most epidemiological studies are limited by their reliance on either patients’ selfreporting of PE or inconsistent and
Classification of Premature
Ejaculation
The population of men with PE is not homoge nous. In 1943, Schapiro classified PE as either primary (lifelong) or secondary (acquired).21 Recently, Waldinger et al. expanded this classifi cation to include lifelong PE, acquired PE, natu ral variable PE, and prematurelike ejaculatory dysfunction (Table 29.1).22 Lifelong PE is a syn drome characterized by a cluster of core symp toms including early ejaculation at nearly every intercourse within 30–60 s in the majority of
C.R. Chapple and W.D. Steers (eds.), Practical Urology: Essential Principles and Practice, |
385 |
DOI: 10.1007/978-1-84882-034-0_29, © Springer-Verlag London Limited 2011 |
|
386
Practical Urology: EssEntial PrinciPlEs and PracticE
Number of men
100
80
60
40
20
0
0 |
200 |
400 |
600 |
800 |
1,000 |
1,200 |
1,400 |
1,600 |
1,800 |
2,000 |
2,200 |
2,400 |
2,600 |
2,800 |
|
|
|
|
|
|
Mean IELT (s) |
|
|
|
|
|
|
Figure 29.1. distribution of intravaginal ejaculatory latency times (iElt) values in a random cohort of 491 men (reprinted from Waldinger et al.10 copyright 2005.With permission from Wiley via copyright clearance center rightslink).
Table 29.1. the four premature ejaculation (PE) syndromes (data from Waldinger22) |
|
|||
Variable |
Lifelong premature |
Acquired premature |
Natural variable |
Premature-like |
|
ejaculation |
ejaculation |
premature ejaculation |
ejaculatory |
|
|
|
|
dysfunction |
iElt |
Very short iElt |
(Very) short iElt |
normal iElt |
normal or long iElt |
|
(<1–1.5 min) |
(<1.5–2 min) |
(3–8 min) |
(3–30 min) |
Frequency |
consistent |
(in)consistent |
inconsistent |
(in)consistent |
Etiology |
neurobiological and |
Medical and/or |
normal variation of |
Psychological |
|
genetic |
psychological |
ejaculatory |
|
|
|
|
performance |
|
treatment |
Medication with or |
Medication and/or |
Psychoeducation, |
Psychotherapy |
|
without counseling |
psychotherapy |
reassurance |
|
Prevalence |
low (?) |
low (?) |
High (?) |
High (?) |
IELT intravaginal ejaculation latency time22.
cases (80%) or between 1 and 2 min (20%), with every or nearly every sexual partner and from the first sexual encounter onwards. Acquired PE differs in that sufferers develop early ejaculation at some point in their life having previously had normal ejaculation experiences. Acquired PE may be due to sexual performance anxiety,23 psychological or relationship problems,23 erec tile dysfunction (ED),24 prostatitis,25 hyperthy roidism,26 or during withdrawal/detoxification from prescribed27 or recreational drugs.28 In a study of 1,326 consecutive men with PE, lifelong
PE was present in 736 men (74.4%),and acquired PE was present in 253 men (25.6%).29 In natural variable PE, the ejaculation time is never consis tently rapid but merely coincidental and situa tional. This type of PE should be regarded as a normal variation in sexual performance and is characterized by inconsistent and irregular early ejaculation, often with reduced ejaculatory con trol.30 Men with prematurelike ejaculatory dys function complain of PE but have a normal ejaculatory latency of 3–6 min. It is character ized by a preoccupation with a subjective but
387
PrEMatUrE EjacUlation
false perception of PE with an ELT within the |
within 1 min.29,46,47 Waldinger et al. (1998) |
||||
normal range but often with reduced ejacula |
reported IELTs <30 s in 77% and <60 s in 90% of |
||||
tory control. |
|
|
110 men with lifelong PE with only 10% ejacu |
||
|
|
|
|
lating between 1 and 2 min.46 McMahon et al. |
|
|
|
|
|
reported similar results in 1,346 consecutive |
|
Defining Premature Ejaculation |
men with predominant ante portal ejaculation |
||||
(during foreplay) in 5.6% of men.29 As such, an |
|||||
Research into the treatment and epidemiology of |
IELT cutoff of 1 min captures 90% of treatment |
||||
seeking men with lifelong PE. Further qualifica |
|||||
PE is heavily dependent on how PE is defined. |
|||||
tion of this cutoff to “about 1 min” affords the |
|||||
The medical literature contains several univariate |
|||||
clinician sufficient flexibility to also diagnose |
|||||
and |
multivariate |
operational |
definitions of |
||
PE in the 10% of PE treatment seeking men who |
|||||
PE.2,20,3137 Although the most commonly quoted |
|||||
ejaculate within 1–2 min of penetration without |
|||||
definition, DSMIVTR, and other definitions of |
|||||
unnecessarily stigmatizing the remaining 90% |
|||||
PE differ substantially, they are all authority |
|||||
of men who ejaculate within 1–2 min of pene |
|||||
based, i.e., expert opinion without explicit critical |
|||||
tration but have no complaints of PE. In office |
|||||
appraisal,38 rather than evidencebased and have |
|||||
practice, the IELT can be reliably estimated by |
|||||
no support from controlled clinical and/or epide |
|||||
men with PE. Several authors report that esti |
|||||
miological studies. This lack of agreement as to |
|||||
mated and stopwatch IELT correlate reasonably |
|||||
what |
constitutes |
PE has hampered clinical |
|||
well or are interchangeable in assigning PE sta |
|||||
research into the etiology and management of |
|||||
tus when estimated IELT is combined with |
|||||
this condition, and the development of patient |
|||||
patient reported outcomes (PROs).4850 |
|||||
reported outcomes (PROs) to diagnose and assess |
|
||||
treatment intervention strategies.39 The first mul |
|
||||
tivariate evidencebased definition of lifelong PE |
Voluntary Control |
||||
was recently reported and characterizes lifelong |
|||||
|
|||||
PE as “… ejaculation which always or nearly |
|
||||
always occurs prior to or within about one min |
The ability to prolong sexual intercourse by |
||||
ute of vaginal penetration, the inability to delay |
|||||
delaying ejaculation and the subjective feelings |
|||||
ejaculation on all or nearly all vaginal penetra |
|||||
of ejaculatory control comprise the complex |
|||||
tions, and the presence of negative personal con |
|||||
construct of ejaculatory control. Virtually all |
|||||
sequences, such as distress, bother, frustration |
|||||
men report using at least one cognitive or behav |
|||||
and/or the avoidance of sexual intimacy.”40 There |
|||||
ioral technique to prolong intercourse and delay |
|||||
is insufficient published evidence to propose an |
|||||
ejaculation, with varying degrees of success, and |
|||||
evidencedbased definition of acquired PE.40 |
|||||
many young men reported using multiple dif |
|||||
|
|
|
|
||
|
|
|
|
ferent techniques.18 |
|
Intravaginal Ejaculatory Latency |
Several authors have suggested that an inabil |
||||
ity to voluntarily defer ejaculation defines PE.5154 |
|||||
|
|
|
|
||
Time (IELT) |
|
|
Patrick et al. reported ratings of “very poor” or |
||
|
|
“poor”for control over ejaculation in 72% of men |
|||
|
|
|
|
with PE compared to 5% in a group of normal |
|
Operationalization of PE measuring the length |
controls.11 However, control is a subjective mea |
||||
of time between penetration and ejaculation |
sure that is difficult to translate into quantifiable |
||||
with a stopwatch, the intravaginal ejaculatory |
terms and is the most inconsistent dimension of |
||||
latency time (IELT), forms the basis of most cur |
PE. Grenier and Byers failed to demonstrate a |
||||
rent clinical studies on PE.41 There is consider |
strong correlation between ejaculatory latency |
||||
able variance of the latencies used to identify |
and subjective ejaculatory control.18,55 Several |
||||
men with PE with IELTs ranging from 1 to 7 min |
authors report that diminished control is not |
||||
and none of the definitions is based on norma |
exclusive to men with PE and that some men |
||||
tive data or offer any supportive rationale for |
with a brief IELT report adequate ejaculatory |
||||
their proposed cutoff time.4245 |
|
control and vice versa,suggesting that the dimen |
|||
Several studies suggest that 80–90% of men |
sions of ejaculatory control and latency are dis |
||||
seeking treatment |
for lifelong |
PE ejaculate |
tinct concepts.11,18 |
388
Practical Urology: EssEntial PrinciPlEs and PracticE
Contrary to this, several authors have |
showed that men with PE had significantly lower |
||
reported a moderate correlation between the |
overall healthrelated quality of life and lower |
||
IELT and the feeling of ejaculatory con |
SelfEsteem And |
Relationship |
Questionnaire |
trol.11,50,56,57 Rosen et al. report that control over |
(SEAR) scores with lower confidence and self |
||
ejaculation, personal distress, and partner dis |
esteem compared |
to nonPE |
groups (all |
tress was more influential in determining PE |
p £0.001).60 The divergent pattern observed for |
||
status than IELT.50 However, despite conflicting |
personal distress suggests that this construct has |
||
data on the relationship between control and |
discriminative validity in diagnosing men with |
||
latency, the balance of evidence supports the |
and without PE. The data for satisfaction and |
||
notion that the inability to delay ejaculation |
interpersonal distress while statistically signifi |
||
appears to differentiate men with PE from men |
cant were not as strong. |
|
|
without PE.11,57,58 |
|
|
|
Sexual Satisfaction
Men with PE report lower levels of sexual satis faction compared to men with normal ejacu latory latency. However, caution should be exercised in assigning lower levels of sexual sat isfaction solely to the effect of PE and contribu tions from other difficulttoquantify issues such as reduced intimacy, dysfunctional rela tionships, poor sexual attraction, and poor com munication should not be ignored. This is supported by the report of Patrick et al. that despite reduced ratings for satisfaction with shorter IELTs with “poor” or “very poor” inter course satisfaction reported by 25.4%, 3.6%, and 2.0% of subjects with an IELT <1 min, >1 min, and >2 min, respectively, a substantial propor tion of men with an IELT <1 min report “good” or “very good” satisfaction ratings (43.7%). Current data are limited but suggests that sexual satisfaction is of limited use in differentiating PE subjects from nonPE subjects and has not been included in the ISSM definition of PE.11
Distress
Premature ejaculation (PE) has been associated with negative psychological outcomes in men and their partners.9,11,12,23,5767 The personal and/ or interpersonal distress that result from PE may affect men’s quality of life and partner relation ships, their selfesteem and selfconfidence, and can act as an obstacle to single men forming new partner relationships.9,11,12,23,5767 Patrick et al. reported that 64% of men with PE versus 4% of nonPE men reported being “quite a bit” or “extremely” personally distressed. Rowland et al.
The Etiology of Premature
Ejaculation
Historically, attempts to explain the etiology of PE has included a diverse range of biological and psychological theories. Most of these pro posed etiologies are not evidence based and are speculative at best. Psychological theories include the effect of early experience and sexual conditioning, anxiety, sexual technique, the fre quency of sexual activity, and psychodynamic explanations. Biological explanations include evolutionary theories, penile hypersensitivity, central neurotransmitter levels and receptor sensitivity, degree of arousability, the speed of the ejaculatory reflex, and the level of sex hormones.
There is little empirical evidence to suggest a causal link between PE and any of the factors thought to cause PE. There is, however, limited correlational evidence to suggest that lifelong PE is genetically determined and related to the inherited altered sensitivity of central 5HT receptors and acquired PE is due to high levels of sexual anxiety, ED, or lower urinary tract infection.
Ejaculatory latency time is probably a biologi cal variable, which is genetically determined and may differ between populations and cultures, ranging from extremely rapid through average to slow ejaculation. This is supported by animal studies showing a subgroup of persistent rapidly ejaculating Wistar rats,6 an increased familial occurrence of lifelong PE,5and a moderate genetic influence on PE in the Finnish twin study.68 Hyposensitivity of the 5HT2C and/or hypersen sitivity of the 5HT1A receptors have been sug gested as a possible explanation of lifelong PE.69,70